Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a video chat program ease the burden of chronic GVHD?

NCT ID NCT04479995

Symptom relief Sponsor: Massachusetts General Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a telehealth program called Horizons for adults who have had a stem cell transplant and developed moderate to severe chronic graft-versus-host disease (GVHD). The program uses video sessions and questionnaires to help patients cope and follow their treatment plan. Researchers will compare it to standard care plus a booklet, aiming to see if the program is feasible and improves quality of life.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Horizons Program (telehealth counseling sessions)
What this could lead to
If it works, this could provide a practical way to help GVHD patients feel better and stick with their treatment.
What could go wrong
This is a small, early feasibility study (80 people) testing a behavioral program, not a new drug. It may not show clear benefits or work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 80 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2020

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

21 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * adult patients (≥ 21 years) who underwent allogeneic HCT * have moderate to severe chronic GVHD * are currently receiving their care at the MGH Blood and Marrow Transplant Clinic * have the ability to participate in an English language group intervention Exclusion Criteria: * Patients with comorbid conditions or cognitive impairment that the treating clinician believes prohibits informed consent or participation in the intervention * Vulnerable patients, defined here as prisoners and pregnant women, will not be included in the intervention

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic graft versus host disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic graft versus host disease disease related to hematopoietic stem cell transplant graft versus host disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Coping skills Graft VS host disease Quality of life Stem cell transplant complications

Contacts and locations

Locations

  • Massachusetts General Hospital Cancer Center

    Boston, Massachusetts, 02114, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.